Literature DB >> 2738686

Beta dose point kernels for radionuclides of potential use in radioimmunotherapy.

W V Prestwich1, J Nunes, C S Kwok.   

Abstract

Beta dose point kernels for 32P, 67Cu, 90Y, 131I, 186Re, and 188Re nuclides appropriate for radioimmunotherapy are calculated based upon Monte Carlo results. The calculations are shown to differ significantly from values based upon solutions to the electron transport equation. Agreement with experiment for 32P is found to be improved for the former as compared with the latter. Values of the scaled dose point kernels are tabulated at 4% intervals of the continuous slowing down approximation range for each of the six radionuclides. Beta dose distributions are also tabulated at corresponding distances from the source. This data may be used to calculate the spatial dose distribution expected following administration of radiolabeled monoclonal antibodies, aiding in optimum selection of the appropriate radionuclide. Parameters for functions providing analytic representation of the calculated scaled dose point kernels of individual beta groups are presented.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738686

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.

Authors:  David M Howard; Kimberlee J Kearfott; Scott J Wilderman; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2011-09-22       Impact factor: 3.099

2.  Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins
Journal:  Cancer Biother Radiopharm       Date:  2011-08-11       Impact factor: 3.099

3.  Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE".

Authors:  Elif Hindié; Christophe Champion; Paolo Zanotti-Fregonara; Domenico Rubello; Nicole Colas-Linhart; Laura Ravasi; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

Review 4.  Radiopharmaceuticals: state of the art.

Authors:  A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1990

5.  Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide.

Authors:  J Tyler French; Beth Goins; Marcela Saenz; Shihong Li; Xavier Garcia-Rojas; William T Phillips; Randal A Otto; Ande Bao
Journal:  J Vasc Interv Radiol       Date:  2010-05-15       Impact factor: 3.464

Review 6.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

7.  Postlumpectomy focal brachytherapy for simultaneous treatment of surgical cavity and draining lymph nodes.

Authors:  Brian A Hrycushko; Shihong Li; Chengyu Shi; Beth Goins; Yaxi Liu; William T Phillips; Pamela M Otto; Ande Bao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

Review 8.  Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.

Authors:  P Multani
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

9.  Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48.

Authors:  M Gerretsen; G W Visser; R H Brakenhoff; M van Walsum; G B Snow; G A van Dongen
Journal:  Cell Biophys       Date:  1994

Review 10.  Biological response modifiers in cancer.

Authors:  Purabi Reang; Madhur Gupta; Kamlesh Kohli
Journal:  MedGenMed       Date:  2006-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.